ArticleBMJ open2025

Rationale and design of a randomised phase II multicentre crossover trial investigating a sodium-glucose co-transporter 2 inhibitor, dapagliflozin, combined with a novel continuous ketone monitor in adults with type 1 diabetes to reduce the risk of diabetic ketoacidosis: the PARTNER study.

Jennifer Ngan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.